HAE Canada is committed to keeping members informed about upcoming clinical research studies for HAE treatments. We are excited to let HAE Canada members know that Phase 3 prophylaxis trial for BCX7353 (APeX-2) has begun in the United States and is currently seeking Canadian participants.
The APeX-2 study is evaluating the safety and effectiveness of an investigational oral medication that may prevent hereditary angioedema (HAE) attacks. You can visit www.haeresearch.com to find important details regarding the research study.
Who is eligible?
If you (or your child) are interested in participating in this clinical research study evaluating an investigational alternative to injections or infusions to prevent HAE attacks, you might be eligible if you:
- Have been diagnosed with HAE Type 1 or 2
- Are 18 years old or older
- Or are the parent or legal guardian of a child 12-17 years old diagnosed with HAE who weighs at least 40 kg or 88 lbs
- Have HAE attacks
- Have access to and can provide your own HAE acute treatment during the study
If you are interested in participating in this important 48 week clinical research study, we ask that you contact your Regional Director listed below: